Clonality and heterogeneity of metachronous colorectal cancer

Abstract

Patients with metachronous colorectal cancer (CRC) have been diagnosed with primary CRC more than once. Given that the genetic and microenvironment is the same in these cases, metachronous CRC is an important model for studying colorectal tumorigenesis. We performed whole exome sequencing of seven freshly frozen tumors from three patients with metachronous CRC and compared their genetic profiles. In patients with metachronous tumors of distinct genetic origins, 3.74% and 0.20% of genes were ubiquitously mutated and candidate cancer genes mutated at different sites. Tumors from the same patients were clonally unrelated, and thus druggable genes differed. In contrast, in a patient with metachronous tumors of a common genetic origin, the ubiquitously mutated genes were 61.02%, with ubiquitously mutated genes and candidate cancer genes all mutated at the same sites, tumors were clonally related, and some druggable genes were the same. Therefore, two different clonal relationships between metachronous tumors exist in CRC, one is monoclonal and the other is polyclonal. Our findings may help to advance understanding of the differences in metachronous CRCs and the genetic mechanisms of which they originate, and provide new avenues for CRC treatment.

Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance

“…Tumour heterogeneity which is the cornerstone for the maintenance of cancer cell populations has been strongly correlated with therapy resistance ( Schumacher et al, 2019 ). Mounting evidence has demonstrated the existence of various forms of tumour heterogeneity with the most frequently observed type being the genetic heterogeneity ( Di et al, 2019 ; Loeb et al, 2019 ). Intra-tumour or inter-tumour genetic status was shown to influence the prognostic outcome and drug response and are determinants of resistance to anti-cancer therapy ( Russo et al, 2016 ; De Angelis et al, 2016 ; Galofré et al, 2020 ; Bruun et al, 2020 ).…”

A Novel Risk Classification Model Predicts Overall Survival and Locoregional Surgery Benefit in Colorectal Patients with Distant Metastasis at the Initial Diagnosis

“…However, because of the tumor heterogeneity as well as various demographic risk factors, standard therapy does not bene t patients of all backgrounds (10,11). E cacy of systemic treatments depends on geography, race, age, and other clinicopathological features (12).…”